|
US7270971B2
(en)
*
|
2003-10-16 |
2007-09-18 |
Merck & Co., Inc. |
Fluorescence assay for measuring the rate of cholesterol ester transfer
|
|
DOP2005000123A
(es)
*
|
2004-07-02 |
2011-07-15 |
Merck Sharp & Dohme |
Inhibidores de cetp
|
|
JP5112307B2
(ja)
*
|
2005-07-01 |
2013-01-09 |
メルク・シャープ・エンド・ドーム・コーポレイション |
Ｃｅｔｐ阻害剤を合成するための方法
|
|
ATE516016T1
(de)
|
2005-12-05 |
2011-07-15 |
Merck Sharp & Dohme |
Selbstemulgierende formulierungen von cetp- hemmern
|
|
AR057218A1
(es)
*
|
2005-12-15 |
2007-11-21 |
Astra Ab |
Compuestos de oxazolidinona y su uso como pontenciadores del receptor metabotropico de glutamato
|
|
WO2007081569A2
(en)
*
|
2005-12-30 |
2007-07-19 |
Merck & Co., Inc. |
Cetp inhibitors
|
|
CA2635262C
(en)
*
|
2005-12-30 |
2011-08-16 |
Merck & Co., Inc. |
1, 3-oxazolidin-2-one derivatives useful as cetp inhibitors
|
|
WO2007081571A2
(en)
*
|
2005-12-30 |
2007-07-19 |
Merck & Co., Inc. |
Cetp inhibitors
|
|
WO2007081570A2
(en)
*
|
2005-12-30 |
2007-07-19 |
Merck & Co., Inc. |
Cholesteryl ester transfer protein inhibitors
|
|
KR101418267B1
(ko)
|
2006-02-09 |
2014-07-11 |
머크 샤프 앤드 돔 코포레이션 |
Ｃｅｔｐ 억제제의 중합체 제형
|
|
US8383660B2
(en)
|
2006-03-10 |
2013-02-26 |
Pfizer Inc. |
Dibenzyl amine compounds and derivatives
|
|
US7919506B2
(en)
|
2006-03-10 |
2011-04-05 |
Pfizer Inc. |
Dibenzyl amine compounds and derivatives
|
|
WO2007136672A2
(en)
*
|
2006-05-19 |
2007-11-29 |
Merck & Co., Inc. |
Synthesis of a biaryl synthetic intermediate
|
|
WO2008082567A1
(en)
*
|
2006-12-29 |
2008-07-10 |
Merck & Co., Inc. |
Process for synthesizing a cetp inhibitor
|
|
WO2008089581A1
(en)
|
2007-01-26 |
2008-07-31 |
Merck Frosst Canada Ltd. |
Fused aromatic ptp-1b inhibitors
|
|
US8759383B2
(en)
|
2007-03-16 |
2014-06-24 |
Concert Pharmaceuticals, Inc. |
Inhibitors of cholesterol ester transfer protein
|
|
WO2008137105A1
(en)
|
2007-05-07 |
2008-11-13 |
Merck & Co., Inc. |
Method of treatment using fused aromatic compounds having anti-diabetic activity
|
|
ES2601856T3
(es)
|
2007-06-08 |
2017-02-16 |
Mannkind Corporation |
Inhibidores de la IRE-1A
|
|
EP2170059B1
(en)
*
|
2007-06-20 |
2014-11-19 |
Merck Sharp & Dohme Corp. |
Cetp inhibitors derived from benzoxazole arylamides
|
|
EP2166847B1
(en)
*
|
2007-06-20 |
2014-11-19 |
Merck Sharp & Dohme Corp. |
Cetp inhibitors derived from benzoxazole arylamides
|
|
US8445480B2
(en)
*
|
2007-06-20 |
2013-05-21 |
Merck Sharp & Dohme Corp. |
CETP inhibitors derived from benzoxazole arylamides
|
|
CN101687844B
(zh)
|
2007-07-02 |
2013-11-13 |
弗·哈夫曼-拉罗切有限公司 |
用作ccr2受体拮抗剂的咪唑衍生物
|
|
WO2009017671A1
(en)
*
|
2007-07-26 |
2009-02-05 |
Vitae Pharmaceuticals, Inc. |
Synthesis of inhibitors of 11beta-hydroxysteroid dehydrogenase type 1
|
|
AR069207A1
(es)
*
|
2007-11-07 |
2010-01-06 |
Vitae Pharmaceuticals Inc |
Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1
|
|
US8440658B2
(en)
|
2007-12-11 |
2013-05-14 |
Vitae Pharmaceuticals, Inc. |
Cyclic urea inhibitors of 11β-hydroxysteroid dehydrogenase 1
|
|
TW200934490A
(en)
*
|
2008-01-07 |
2009-08-16 |
Vitae Pharmaceuticals Inc |
Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1
|
|
US8592409B2
(en)
*
|
2008-01-24 |
2013-11-26 |
Vitae Pharmaceuticals, Inc. |
Cyclic carbazate and semicarbazide inhibitors of 11β-hydroxysteroid dehydrogenase 1
|
|
GB2460597B8
(en)
*
|
2008-02-01 |
2014-03-12 |
Amira Pharmaceuticals Inc |
N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors
|
|
JP5491416B2
(ja)
*
|
2008-02-01 |
2014-05-14 |
パンミラ ファーマシューティカルズ，エルエルシー． |
プロスタグランジンｄ２受容体のｎ，ｎ−２置換アミノアルキルビフェニルアンタゴニスト
|
|
JP5734666B2
(ja)
*
|
2008-02-11 |
2015-06-17 |
ヴァイティー ファーマシューティカルズ，インコーポレイテッド |
１１β−ヒドロキシステロイドデヒドロゲナーゼ１の１，３−オキサアゼパン−２−オン及び１，３−ジアゼパン−２−オン阻害剤
|
|
JP2011512359A
(ja)
|
2008-02-14 |
2011-04-21 |
アミラ ファーマシューティカルズ，インク． |
プロスタグランジンｄ２受容体のアンタゴニストとしての環式ジアリールエーテル化合物
|
|
CA2715290A1
(en)
*
|
2008-02-15 |
2009-08-20 |
Vitae Pharmaceuticals, Inc. |
Inhibitors of 11beta-hydroxysteroid dehydrogenase 1
|
|
JP2011513242A
(ja)
*
|
2008-02-25 |
2011-04-28 |
アミラ ファーマシューティカルズ，インク． |
プロスタグランジンｄ２受容体アンタゴニスト
|
|
WO2009117109A1
(en)
*
|
2008-03-18 |
2009-09-24 |
Vitae Pharmaceuticals, Inc. |
Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1
|
|
JP2011518130A
(ja)
|
2008-04-02 |
2011-06-23 |
アミラ ファーマシューティカルズ，インク． |
プロスタグランジンｄ２受容体のアミノアルキルフェニルアンタゴニスト
|
|
CA2723034A1
(en)
|
2008-05-01 |
2009-11-05 |
Vitae Pharmaceuticals, Inc. |
Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
|
|
EP2291371B1
(en)
|
2008-05-01 |
2015-06-10 |
Vitae Pharmaceuticals, Inc. |
Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
|
|
JP5301563B2
(ja)
|
2008-05-01 |
2013-09-25 |
ヴァイティー ファーマシューティカルズ，インコーポレイテッド |
１１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状インヒビター
|
|
US8063088B2
(en)
|
2008-06-11 |
2011-11-22 |
Hoffmann-La Roche Inc. |
Imidazolidine derivatives
|
|
WO2010010150A1
(en)
|
2008-07-25 |
2010-01-28 |
Boehringer Ingelheim International Gmbh |
Synthesis of inhibitors of 11beta-hydroxysteroid dehydrogenase type 1
|
|
PL2324018T3
(pl)
|
2008-07-25 |
2014-02-28 |
Boehringer Ingelheim Int |
Cykliczne inhibitory dehydrogenazy 11 beta-hydroksysteroidowej typu 1
|
|
CA2729998A1
(en)
|
2008-07-25 |
2010-01-28 |
Boehringer Ingelheim International Gmbh |
Inhibitors of 11beta-hydroxysteroid dehydrogenase 1
|
|
GB2463788B
(en)
|
2008-09-29 |
2010-12-15 |
Amira Pharmaceuticals Inc |
Heteroaryl antagonists of prostaglandin D2 receptors
|
|
DE102008049675A1
(de)
|
2008-09-30 |
2010-04-01 |
Markus Dr. Heinrich |
Verfahren zur Herstellung von 3-Aminobiphenylen
|
|
US8378107B2
(en)
|
2008-10-01 |
2013-02-19 |
Panmira Pharmaceuticals, Llc |
Heteroaryl antagonists of prostaglandin D2 receptors
|
|
WO2010039474A1
(en)
*
|
2008-10-01 |
2010-04-08 |
Merck Sharp & Dohme Corp. |
Prodrugs of oxazolidinone cetp inhibitors
|
|
US8524748B2
(en)
|
2008-10-08 |
2013-09-03 |
Panmira Pharmaceuticals, Llc |
Heteroalkyl biphenyl antagonists of prostaglandin D2 receptors
|
|
US8410284B2
(en)
|
2008-10-22 |
2013-04-02 |
Merck Sharp & Dohme Corp |
Cyclic benzimidazole derivatives useful as anti-diabetic agents
|
|
EP2362731B1
(en)
|
2008-10-31 |
2016-04-06 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
|
US8383654B2
(en)
|
2008-11-17 |
2013-02-26 |
Panmira Pharmaceuticals, Llc |
Heterocyclic antagonists of prostaglandin D2 receptors
|
|
TW201028414A
(en)
|
2009-01-16 |
2010-08-01 |
Merck Sharp & Dohme |
Oxadiazole beta carboline derivatives as antidiabetic compounds
|
|
CA2749891A1
(en)
|
2009-01-23 |
2010-07-29 |
Hubert B. Josien |
Bridged and fused antidiabetic compounds
|
|
EP2389226B1
(en)
|
2009-01-23 |
2013-11-20 |
Merck Sharp & Dohme Corp. |
Bridged and fused heterocyclic antidiabetic compounds
|
|
JP5679997B2
(ja)
|
2009-02-04 |
2015-03-04 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
１１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状阻害剤
|
|
EP2393810A1
(en)
|
2009-02-05 |
2011-12-14 |
Schering Corporation |
Phthalazine-containing antidiabetic compounds
|
|
MA33216B1
(fr)
|
2009-04-30 |
2012-04-02 |
Boehringer Ingelheim Int |
Inhibiteurs cycliques de la 11béta-hydroxysteroïde déshydrogénase 1
|
|
WO2011011123A1
(en)
|
2009-06-11 |
2011-01-27 |
Vitae Pharmaceuticals, Inc. |
Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 based on the 1,3 -oxazinan- 2 -one structure
|
|
EP2448928B1
(en)
|
2009-07-01 |
2014-08-13 |
Vitae Pharmaceuticals, Inc. |
Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
|
|
WO2011017201A2
(en)
*
|
2009-08-05 |
2011-02-10 |
Amira Pharmaceuticals, Inc. |
Dp2 antagonist and uses thereof
|
|
JP2011057661A
(ja)
|
2009-08-14 |
2011-03-24 |
Bayer Cropscience Ag |
殺虫性カルボキサミド類
|
|
WO2011056737A1
(en)
|
2009-11-05 |
2011-05-12 |
Boehringer Ingelheim International Gmbh |
Novel chiral phosphorus ligands
|
|
CN102695414A
(zh)
|
2010-01-15 |
2012-09-26 |
默沙东公司 |
作为抗糖尿病化合物的噁二唑β-咔啉衍生物
|
|
JP2013520502A
(ja)
|
2010-02-25 |
2013-06-06 |
メルク・シャープ・エンド・ドーム・コーポレイション |
有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
|
|
JP2013531636A
(ja)
|
2010-05-26 |
2013-08-08 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
２−オキソ−１，２−ジヒドロピリジン−４−イルボロン酸誘導体
|
|
EP2397473A1
(en)
|
2010-06-14 |
2011-12-21 |
LEK Pharmaceuticals d.d. |
A stable highly crystalline anacetrapib
|
|
US8933072B2
(en)
|
2010-06-16 |
2015-01-13 |
Vitae Pharmaceuticals, Inc. |
Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
|
|
EP2585444B1
(en)
|
2010-06-25 |
2014-10-22 |
Boehringer Ingelheim International GmbH |
Azaspirohexanones as inhibitors of 11-beta-hsd1 for the treatment of metabolic disorders
|
|
JPWO2012046681A1
(ja)
|
2010-10-04 |
2014-02-24 |
興和株式会社 |
脂質代謝関連ｍＲＮＡの発現抑制剤
|
|
US9221834B2
(en)
|
2010-10-29 |
2015-12-29 |
Merck Sharp & Dohme Corp. |
Cyclic amine substituted oxazolidinone CETP inhibitor
|
|
WO2012059416A1
(en)
|
2010-11-02 |
2012-05-10 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical combinations for the treatment of metabolic disorders
|
|
EP2468735A1
(en)
|
2010-12-23 |
2012-06-27 |
LEK Pharmaceuticals d.d. |
Synthesis of intermediates for preparing anacetrapib and derivates thereof
|
|
EP2468736A1
(en)
|
2010-12-23 |
2012-06-27 |
LEK Pharmaceuticals d.d. |
Synthesis of intermediates for preparing anacetrapib and derivates thereof
|
|
US9052326B2
(en)
|
2011-01-26 |
2015-06-09 |
Institut National De La Santé Et De La Recherche Médicale (Inserm) |
Method for assessing a subject's risk of having a cardiovascular disease
|
|
SG192941A1
(en)
|
2011-02-25 |
2013-09-30 |
Merck Sharp & Dohme |
Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
|
|
PT2697207T
(pt)
*
|
2011-04-12 |
2017-02-14 |
Chong Kun Dang Pharmaceutical Corp |
Derivados de 3-(2-aril-cicloalcenilmetil)-oxazolidin-2-ona como inibidores da proteína de transferência de ésteres de colesterol (cetp)
|
|
JPWO2013005834A1
(ja)
*
|
2011-07-07 |
2015-02-23 |
持田製薬株式会社 |
高純度ｅｐａを含有する抗肥満剤
|
|
TWI627167B
(zh)
|
2011-07-08 |
2018-06-21 |
諾華公司 |
用於高三酸甘油酯個體治療動脈粥狀硬化之方法
|
|
JO3210B1
(ar)
|
2011-10-28 |
2018-03-08 |
Merck Sharp & Dohme |
مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة
|
|
US9145348B2
(en)
*
|
2011-10-31 |
2015-09-29 |
Merck Sharpe & Dohme Corp. |
Process for synthesizing a CETP inhibitor
|
|
WO2013064188A1
(en)
|
2011-11-03 |
2013-05-10 |
Lek Pharmaceuticals D.D. |
A stable highly crystalline anacetrapib
|
|
JPWO2013080999A1
(ja)
|
2011-11-29 |
2015-04-27 |
興和株式会社 |
ＮＰＣ１Ｌ１及び／又はＬＩＰＧｍＲＮＡの発現抑制剤並びに肥満症の予防及び／又は治療剤
|
|
BR112014012082A2
(pt)
*
|
2011-11-30 |
2017-05-30 |
Dae Woong Pharma |
composição farmacêutica e método para prevenir ou tratar hipertrigliceridemia ou doença associada a hipertricliceridemia e uso de comporto ou seu sal farmaceuticamente aceitável e bloqueador do canal de cálcio ou fibrato
|
|
WO2013091696A1
(en)
|
2011-12-21 |
2013-06-27 |
Lek Pharmaceuticals D.D. |
Synthesis of intermediates for preparing anacetrapib and derivatives thereof
|
|
EP2844252B1
(en)
|
2012-05-02 |
2016-11-30 |
Merck Sharp & Dohme Corp. |
Cyclic amine substituted heterocyclic compounds as cetp inhibitors
|
|
MX347400B
(es)
|
2012-06-29 |
2017-04-18 |
Univ Nac Autónoma De México |
Vacuna de aplicacion nasal contra el desarrollo de la enfermedad aterosclerotica y el higado graso.
|
|
WO2014012428A1
(zh)
*
|
2012-07-19 |
2014-01-23 |
上海恒瑞医药有限公司 |
噁唑烷酮类衍生物、其制备方法及其在医药上的应用
|
|
EP2888006B1
(en)
|
2012-08-22 |
2019-04-24 |
Merck Sharp & Dohme Corp. |
Novel azabenzimidazole tetrahydropyran derivatives useful as ampk activators
|
|
EP2934518B1
(en)
|
2012-12-19 |
2020-02-19 |
Merck Sharp & Dohme Corp. |
Spirocyclic cetp inhibitors
|
|
WO2014099834A1
(en)
|
2012-12-20 |
2014-06-26 |
Merck Sharp & Dohme Corp. |
Therapeutic thiazolidinone compounds
|
|
WO2014111953A1
(en)
*
|
2013-01-17 |
2014-07-24 |
Glenmark Pharmaceuticals Limited; Glenmark Generics Limited |
Process for preparation of anacetrapib and intermediates thereof
|
|
HRP20171102T1
(hr)
*
|
2013-01-31 |
2017-10-20 |
Chong Kun Dang Pharmaceutical Corp. |
Biaril- ili heterociklički biaril-supstituirani spojevi derivata cikloheksena kao inhibitori cetp
|
|
EP2970119B1
(en)
|
2013-03-14 |
2021-11-03 |
Merck Sharp & Dohme Corp. |
Novel indole derivatives useful as anti-diabetic agents
|
|
WO2015017302A2
(en)
|
2013-07-30 |
2015-02-05 |
Merck Sharp & Dohme Corp. |
Bicyclic ureas and thiadiazolidine-1,1-dioxides as cetp inhibitors
|
|
WO2015054088A1
(en)
|
2013-10-10 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
3,3'-disubstituted indolines as inhibitors of cholesterol ester transfer protein
|
|
US9663534B2
(en)
|
2013-12-17 |
2017-05-30 |
Merck Sharp & Dohme Corp. |
Fused bicyclic isoxazolines as inhibitors of cholesterol ester transfer protein
|
|
CN104955816B
(zh)
*
|
2014-01-14 |
2016-08-31 |
杭州普晒医药科技有限公司 |
一种安塞曲匹的晶型及其制备方法、其药物组合物和用途
|
|
CN103923030B
(zh)
*
|
2014-03-27 |
2015-07-22 |
汕头经济特区鮀滨制药厂 |
一种安塞曲匹的关键中间体的合成方法
|
|
CN103923031A
(zh)
*
|
2014-04-01 |
2014-07-16 |
汕头经济特区鮀滨制药厂 |
一种安塞曲匹的中间体的合成方法
|
|
EP3174537B1
(en)
*
|
2014-07-29 |
2021-06-23 |
Merck Sharp & Dohme Corp. |
Monocyclic isoxazolines as inhibitors of cholesterol ester transfer protein
|
|
CN106559998B
(zh)
|
2014-07-30 |
2022-01-25 |
豪夫迈·罗氏有限公司 |
预测对hdl升高剂或hdl模拟剂疗法的应答性的遗传标记
|
|
CN104230835B
(zh)
*
|
2014-09-01 |
2017-01-25 |
福建师范大学 |
一种合成n‑苯乙烯基恶唑烷‑2‑酮衍生物的方法
|
|
WO2016067194A1
(en)
*
|
2014-10-27 |
2016-05-06 |
Sun Pharmaceutical Industries Limited |
Process for the preparation of anacetrapib and an intermediate thereof
|
|
CN106032362B
(zh)
*
|
2015-03-10 |
2018-06-19 |
湖南千金湘江药业股份有限公司 |
安塞曲匹的制备方法
|
|
EP3478676A1
(en)
|
2016-06-29 |
2019-05-08 |
Orion Corporation |
Benzodioxane derivatives and their pharmaceutical use
|
|
KR101902002B1
(ko)
*
|
2016-07-19 |
2018-09-27 |
재단법인 대구경북첨단의료산업진흥재단 |
Cetp 억제제로서의 옥사졸리딘온 유도체 화합물
|
|
JP6945619B2
(ja)
*
|
2016-08-17 |
2021-10-06 |
ノバルティス アーゲー |
Ｎｅｐ阻害剤合成のための新規な方法および中間体
|
|
CN106496211A
(zh)
*
|
2016-10-18 |
2017-03-15 |
湖南德魅信息技术有限公司 |
二氟甲基取代的噁唑烷酮化合物及其用途
|
|
CN106496154A
(zh)
*
|
2016-10-18 |
2017-03-15 |
湖南德魅信息技术有限公司 |
安塞曲匹的制备方法
|
|
CN106749075A
(zh)
*
|
2016-11-24 |
2017-05-31 |
山东新华制药股份有限公司 |
阿那曲波的恶唑烷酮中间体的晶型及其制备方法
|
|
WO2019043018A1
(en)
|
2017-08-29 |
2019-03-07 |
Dalcor Pharma Uk Ltd., Stockport Zug Branch |
METHODS OF TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND REDUCING THE RISK OF CARDIOVASCULAR EVENTS
|
|
JOP20180092A1
(ar)
|
2017-10-13 |
2019-04-13 |
Gilead Sciences Inc |
مثبطات hiv بروتياز
|
|
SG11202101086YA
(en)
|
2018-08-09 |
2021-03-30 |
Dalcor Pharma Uk Ltd Leatherhead |
Methods for delaying occurrence of new-onset type 2 diabetes and for slowing progression of and treating type 2 diabetes
|
|
CA3126323A1
(en)
|
2019-03-07 |
2020-09-10 |
Jean-Claude Tardif |
Methods for treating or preventing heart failure and reducing risk of heart failure
|
|
TW202104210A
(zh)
|
2019-04-17 |
2021-02-01 |
美商基利科學股份有限公司 |
Hiv蛋白酶抑制劑
|
|
CN119462782A
(zh)
|
2019-07-19 |
2025-02-18 |
生物合成股份公司 |
制备烟酰胺呋喃核糖苷盐的方法、烟酰胺呋喃核糖苷盐本身及其用途
|
|
CN115916754A
(zh)
|
2020-05-05 |
2023-04-04 |
纽威伦特公司 |
杂芳族大环醚化学治疗剂
|
|
BR112022022530A2
(pt)
|
2020-05-05 |
2023-02-23 |
Nuvalent Inc |
Composto, composição farmacêutica, método de tratamento de câncer, método de inibição seletiva, método de redução de um nível de ros1 ou alk
|
|
WO2022075645A1
(ko)
*
|
2020-10-08 |
2022-04-14 |
재단법인 대구경북첨단의료산업진흥재단 |
Pcsk9 억제제로서 아미노알콜 유도체 및 이를 함유하는 고콜레스테롤 혈증의 예방 또는 치료용 약학적 조성물
|
|
US20240360103A1
(en)
*
|
2021-06-30 |
2024-10-31 |
Apellis Pharmaceuticals, Inc. |
Complement inhibition
|
|
MX2024003738A
(es)
|
2021-10-01 |
2024-06-19 |
Nuvalent Inc |
Formas solidas, composiciones farmaceuticas y preparacion de compuestos de eter macrociclico heteroaromatico.
|
|
WO2025093129A1
(en)
|
2023-11-01 |
2025-05-08 |
Newamsterdam Pharma B.V. |
Treatment and prevention of age-related macular degeneration using a cetp inhibitor
|